Genome editing or small molecule inhibition of KMT5A in CAR-T cells enhances antitumor immunity
Open Access
- 12 September 2025
- journal article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (9) , e012160
Abstract
Background: Adoptive T-cell therapy has emerged as a promising therapeutic strategy for cancer treatment. However, clinical challenges persist, including the limited ability of CD8+T cells to infiltrate solid tumors and efficiently eliminate tumor cells. Given the critical role of epigenetic mechanisms in antitumor immunity, targeting epigenetic regulators represents a critical step toward optimizing adoptive T-cell therapies for solid tumors. Methods: To investigate the role of KMT5A in CD8+T cell function, we employed CRISPR screening to identify KMT5A as a negative regulator. We then genetically deleted KMT5A in human CD8+T cells and systematically evaluated its impact on the antitumor efficacy of chimeric antigen receptor (CAR)-T cells using xenograft models. Furthermore, we used the small-molecule inhibitor UNC0379 to pharmacologically inhibit KMT5A, meticulously assessing the consequent effects on CAR-T cell activation, cytotoxicity, and antitumor activity. Results: We report that lysine methyltransferase KMT5A acts as a negative regulator of CD8+T cell function, identified via CRISPR screening. KMT5A deletion in human CD8+T cells significantly enhances the antitumor efficacy of CAR CD8+T cells in xenograft models. In vitro immunophenotyping reveals that KMT5A deletion improves effector functions, cytokine secretion, and early activation of CD8+T cells. Mechanistically, KMT5A depletion increases the expression and chromatin accessibility of multiple effector-related genes in CD8+T cells. KMT5A-mediated histone H4 modifications and chromatin remodeling suppress CD8+T cell effector functions, partially via inhibition of the transcription factor SP1. Notably, pharmacological inhibition of KMT5A using the small-molecule inhibitor UNC0379 enhanced activation, cytotoxicity, and antitumor activity in human CD8+T cells—a novel finding in this study. Conclusions: Our findings establish KMT5A as an epigenetic regulator that impairs CD8+T cell function. These findings demonstrate that genetic or pharmacological (eg, UNC0379) targeting of KMT5A in CD8+T cells represents a viable therapeutic strategy to augment effector functions and improve adoptive T-cell therapies, particularly CAR-T cells, for solid tumors.Keywords
Funding Information
- Natural Science Foundation of China (82270125)
- Shanghai Municipal Commission for Science and Technology (23HC1400400)
- Key R&D Program of China (2023YFC3403400, 2023YFC3403401, 2024YFA1803300, 2024YFA1803301)
This publication has 55 references indexed in Scilit:
- Accelerating CAR-T Cell Therapies with Small-Molecule InhibitorsBioDrugs, 2024
- Revisiting IRF1-mediated antiviral innate immunityCytokine & Growth Factor Reviews, 2022
- In vivo CD8+ T cell CRISPR screening reveals control by Fli1 in infection and cancerCell, 2021
- Memory T cells: strategies for optimizing tumor immunotherapyProtein & Cell, 2020
- Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T CellsCell, 2019
- Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune FunctionCell, 2018
- The Fate Choice Between Effector and Memory T Cell Lineages: Asymmetry, Signal Integration, and Feedback to Create Bistability2018
- Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk NeuroblastomaCancer Cell, 2017
- PR‐Set7‐mediated monomethylation of histone H4 lysine 20 at specific genomic regions induces transcriptional repressionJournal of Cellular Biochemistry, 2010
- Relationship between CD107a expression and cytotoxic activityCellular Immunology, 2009